BioRestorative Completes Phase II Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies, Inc. announced that the last patient has been dosed in its fully enrolled Phase II clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease, completing treatment administration in the Company’s lead clinical program.